Biotricity Achieves Cashflow Breakeven with Record Revenue Growth
Redwood City, Monday, 17 February 2025.
Biotricity’s Q3-FY25 sees a 22% revenue increase to $3.6 million, achieving cashflow breakeven. This marks a major financial milestone, showcasing its strategic advancement in medical technology.
Record-Breaking Quarter Details
Biotricity Inc. (OTCQB: BTCY), a Technology-as-a-Service company in the remote cardiac monitoring sector, has reported significant financial progress for its third quarter of fiscal year 2025 [1]. The company achieved a 22% year-over-year revenue growth to $3.6 million, alongside an 11% sequential increase from the previous quarter [1][2]. Most notably, Biotricity anticipates reporting positive cash flow for Q3-FY25 on a current operating basis, excluding interest, dividends, and amortization [1].
Strategic Growth and Market Position
The company’s improving financial metrics reflect its strengthening position in the medical technology sector. With a market capitalization of $9.58 million [5], Biotricity is actively competing in the surgical and medical instruments industry. Dr. Waqaas Al-Siddiq, Biotricity’s Founder & CEO, emphasized the company’s commitment to innovation, stating their continued focus on driving revenue and margins while developing transformative healthcare technologies [2].
Financial Outlook and Upcoming Reports
Investors and stakeholders can expect detailed insights into the company’s performance very soon. Biotricity will release its full financial results on February 19, 2025, via Form 10-Q filing with the SEC [1][2]. A financial results conference call is scheduled for February 20, 2025, at 5:30 PM ET, where management will provide a comprehensive business update [1]. The call replay will be available approximately three hours after the live session and accessible until March 6, 2025, at 11:59 PM ET [2].